Nearly half of patients in the IMpassion130 trial had PD-L1 assessed in the primary tumour, and PD-L1 positivity in either primary or metastatic tumour was associated with improved survival with atezolizumab [11]. The gene discussed is CD274; the disease is metastatic neoplasm.